Saturday, July 11, 2026

Drug profile · INN

tipiracil hydrochloride

tipiracil hydrochloride (LONSURF) is a thymidine phosphorylase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tipiracil hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

tipiracil hydrochloride (LONSURF) is a thymidine phosphorylase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN tipiracil hydrochloride
Brand LONSURF
Mechanism Thymidine phosphorylase inhibitor
Target Thymidine phosphorylase
Route ORAL
Formulation TABLET

Mechanism of action

Thymidine phosphorylase inhibitor

Primary target: Thymidine phosphorylase

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is tipiracil hydrochloride?

tipiracil hydrochloride (LONSURF) is a thymidine phosphorylase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for tipiracil hydrochloride?

LONSURF is a marketed brand name for tipiracil hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tipiracil hydrochloride?

tipiracil hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.